Dr. Bourlon on follow-up data from the CheckMate 9ER trial in RCC

In this video, María Teresa Bourlon, MD, Msc, MS, highlights key findings from the study, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial,” which was presented at the 2024 ASCO Genitourinary Cancers Symposium in San Francisco, California. Bourlon is a medical oncologist at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico.

Video Transcript:

This was a phase 3 randomized study of nivolumab plus cabozantinib vs sunitinib in advanced untreated renal cell carcinoma. We know that the primary analysis of this study favored cabo/nivo over sunitinib in efficacy end points [such] as progression-free survival, overall survival, and overall response rate. I think it's reassuring that the benefit in these outcomes is maintained at 55-months follow-up. It's also remarkable that this combination led to better health-related quality of life in patients receiving cabo/nivo vs those receiving sunitinib in this study.

It's also impressive for the cabo/nivo combination that there's a low rate of progressive disease; around 6% to 7% of the patients had progressive disease, in contrast to 13 to 14%, that will have progressive disease on the sunitinib arm. It's always good to see that few patients are going to present progressive disease as best response. I think it's very interesting to see that we continue to see a survival benefit at 55-months follow-up. It's also reassuring to see that we have benefit on RCC specific health-related quality of life and also general health-related quality of life instruments with this combination therapy over sunitinib. I think that's something very important to highlight for this treatment strategy.

This transcription has been edited for clarity.